For Immediate Release
Canadian Breast Cancer Network commends Québec Ministry of Health for commitment on metastatic breast cancer
The Canadian Breast Cancer Network (CBCN) commends the Québec Ministry of Health for their actions to increase access to new metastatic breast cancer treatments in the province.
Effective July 24th, the Québec Ministry of Health announced that they will provide access to Perjeta (pertuzumab) for HER-2 positive, metastatic breast cancer patients.
The decision to provide Québec residents living with metastatic breast cancer greater access to new treatment options is a step in the right direction and will have an enormous impact on people battling serious illnesses. “We are so pleased to have worked with the Ministry of Health to promote access to metastatic breast cancer treatments in Québec,” said Cathy Ammendolea, Board Chair and Québec representative for the Canadian Breast Cancer Network. “With this decision, Québec has demonstrated great commitment towards improving patient outcomes and ensuring that women living with metastatic breast cancer in the province can quickly and affordably access the potentially life-saving treatments they need.”
Providing access to new and more effective treatments gives patients a fighting chance to live much longer and spend precious time with loved ones. The Canadian Breast Cancer Network urges all provinces and jurisdictions to ensure that essential treatments for metastatic breast cancer are added to all their drug formularies.
For more information, please contact CBCN at 613-230-3044 or NChari@cbcn.ca.
About the Canadian Breast Cancer Network
The Canadian Breast Cancer Network is the leading survivor-directed, national network of organizations and individuals concerned about breast cancer. The Canadian Breast Cancer Network exists to voice the concerns of breast cancer patients and survivors and promote the best quality of care for all Canadians affected by breast cancer.